Morgan Stanley Xeris Biopharma Holdings, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,288,281 shares of XERS stock, worth $19.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,288,281

Previous 2,877,516 49.03%

Holding current value

$19.8 Million

Previous $9.75 Million 141.36%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$3.2 - $5.95 $4.51 Million - $8.39 Million	1,410,765 Added 49.03%	4,288,281 $23.5 Million
Q4 2024 Feb 14, 2025	BUY	$2.78 - $3.73 $1.45 Million - $1.95 Million	523,208 Added 22.22%	2,877,516 $9.75 Million
Q3 2024 May 14, 2025	BUY	$2.06 - $2.96 $1.53 Million - $2.2 Million	744,384 Added 46.24%	2,354,308 $6.71 Million
Q3 2024 Nov 14, 2024	BUY	$2.06 - $2.96 $1.53 Million - $2.2 Million	744,384 Added 46.24%	2,354,308 $6.71 Million
Q2 2024 May 14, 2025	SELL	$1.7 - $2.45 $2.15 Million - $3.11 Million	-1,267,592 Reduced 44.05%	1,609,924 $3.62 Million
Q2 2024 Oct 17, 2024	BUY	$1.7 - $2.45 $542,242 - $781,466	318,966 Added 24.71%	1,609,924 $3.62 Million
Q2 2024 Aug 14, 2024	BUY	$1.7 - $2.45 $542,242 - $781,466	318,966 Added 24.71%	1,609,924 $3.62 Million
Q1 2024 Oct 17, 2024	SELL	$2.04 - $3.22 $650,690 - $1.03 Million	-318,966 Reduced 19.81%	1,290,958 $2.85 Million
Q1 2024 Aug 16, 2024	BUY	$2.04 - $3.22 $141,984 - $224,112	69,600 Added 5.7%	1,290,958 $2.85 Million
Q1 2024 May 15, 2024	BUY	$2.04 - $3.22 $141,984 - $224,112	69,600 Added 5.7%	1,290,958 $2.85 Million
Q4 2023 Aug 16, 2024	SELL	$1.47 - $2.36 $571,192 - $917,015	-388,566 Reduced 24.14%	1,221,358 $2.87 Million
Q4 2023 Feb 13, 2024	BUY	$1.47 - $2.36 $857,195 - $1.38 Million	583,126 Added 91.37%	1,221,358 $2.87 Million
Q3 2023 Nov 15, 2023	BUY	$1.8 - $2.69 $552,321 - $825,413	306,845 Added 92.59%	638,232 $1.19 Million
Q2 2023 Aug 14, 2023	BUY	$1.82 - $2.98 $322,225 - $527,600	177,047 Added 114.71%	331,387 $868,000
Q1 2023 May 15, 2023	BUY	$1.03 - $1.63 $36,649 - $57,998	35,582 Added 29.96%	154,340 $251,000
Q4 2022 Feb 14, 2023	BUY	$1.14 - $1.65 $1,354 - $1,960	1,188 Added 1.01%	118,758 $157,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $1.93 $13,208 - $18,607	-9,641 Reduced 7.58%	117,570 $185,000
Q2 2022 Oct 27, 2022	SELL	$1.48 - $2.64 $19,710 - $35,159	-13,318 Reduced 9.48%	127,211 $195,000
Q2 2022 Aug 15, 2022	SELL	$1.48 - $2.64 $19,710 - $35,159	-13,318 Reduced 9.48%	127,211 $195,000
Q1 2022 Oct 27, 2022	BUY	$2.0 - $2.87 $26,636 - $38,222	13,318 Added 10.47%	140,529 $360,000
Q1 2022 May 13, 2022	SELL	$2.0 - $2.87 $2.42 Million - $3.47 Million	-1,210,258 Reduced 89.6%	140,529 $360,000
Q4 2021 Feb 14, 2022	BUY	$1.8 - $2.93 $2.43 Million - $3.96 Million	1,350,787 New	1,350,787 $3.96 Million

Others Institutions Holding XERS

# of Institutions

204

Shares Held

84.7M

Call Options Held

132K

Put Options Held

69.4K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $628M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account